Found 19 hits for monomerid = 3160 Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Protein kinase C alpha type
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt UniProtKB/TrEMBL
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 100 | n/a | n/a | n/a | n/a | 7.5 | 30 |
Sphinx Laboratories
| Assay Description PKC was assayed by quantitating the incorporation of 32P from [gamma-32P]ATP into histone type IIIs. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
cAMP-dependent protein kinase (PKA)
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB
KEGG
UniProtKB/SwissProt UniProtKB/TrEMBL
B.MOAD antibodypedia antibodypedia antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 3.20E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Sphinx Laboratories
| Assay Description Inhibition of Protein kinase C zeta |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
PKC alpha and beta-2
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 30 | n/a | n/a | n/a | n/a | 7.5 | 30 |
Sphinx Laboratories
| Assay Description PKC was assayed by quantitating the incorporation of 32P from [gamma-32P]ATP into histone type IIIs. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
Protein kinase C, gamma
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
Sphinx Laboratories
| Assay Description PKC was assayed by quantitating the incorporation of 32P from [gamma-32P]ATP into histone type IIIs. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
Protein kinase C delta type
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt UniProtKB/TrEMBL
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
Sphinx Laboratories
| Assay Description PKC was assayed by quantitating the incorporation of 32P from [gamma-32P]ATP into histone type IIIs. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
Protein kinase C, epsilon
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt UniProtKB/TrEMBL
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 970 | n/a | n/a | n/a | n/a | n/a | n/a |
Sphinx Laboratories
| Assay Description PKC was assayed by quantitating the incorporation of 32P from [gamma-32P]ATP into histone type IIIs. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
Protein kinase C, eta
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
Sphinx Laboratories
| Assay Description PKC was assayed by quantitating the incorporation of 32P from [gamma-32P]ATP into histone type IIIs. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
Protein kinase C (PKC)
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 3.70E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Sphinx Laboratories
| Assay Description PKC was assayed by quantitating the incorporation of 32P from [gamma-32P]ATP into histone type IIIs. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
cAMP-Dependent Protein Kinase (PKA)
(Bos taurus (bovine)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB
UniProtKB/SwissProt
GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 3.20E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Sphinx Laboratories
| Assay Description The activity of PKA, activated by cAMP, is measured by its ability to transfer phosphate from [gamma-32P]ATP to histone. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |
Protein kinase C alpha type
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt UniProtKB/TrEMBL
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration against recombinant human Protein kinase C alpha isozyme |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
PKC alpha and beta-2
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 30 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration against recombinant human Protein kinase C beta 2 isozyme |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
Protein kinase C, eta
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration against recombinant human Protein kinase C eta isozyme |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
Protein kinase C delta type
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt UniProtKB/TrEMBL
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration against recombinant human Protein kinase C delta isozyme |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
PKC alpha and beta-2
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 150 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration against recombinant human Protein kinase C beta 1 isozyme |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
Protein kinase C, epsilon
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt UniProtKB/TrEMBL
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 970 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration against recombinant human Protein kinase C epsilon isozyme |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
cAMP-dependent protein kinase (PKA)
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt UniProtKB/TrEMBL
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 3.20E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration of the compound against recombinant human cAMP-dependent Protein kinase A |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
Protein kinase C, gamma
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 50 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration against recombinant human Protein kinase C gamma isozyme |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
Protein kinase C (PKC)
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article PubMed
| n/a | n/a | 3.70E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
A Division of Eli Lilly & Company
Curated by ChEMBL
| Assay Description Inhibitory concentration against recombinant human Protein kinase C zeta isozyme |
J Med Chem 40: 226-35 (1997)
Article DOI: 10.1021/jm960497g BindingDB Entry DOI: 10.7270/Q2J965HR |
More data for this Ligand-Target Pair | |
PKC alpha and beta-2
(Homo sapiens (Human)) | BDBM3160
(2-{[2,6-dihydroxy-4-({[(8R,9R)-9-[(4-hydroxybenzen...)Show SMILES OC(=O)c1cccc(O)c1C(=O)c1c(O)cc(cc1O)C(=O)O[C@@H]1C2CC(C3CCCC23)[C@H]1NC(=O)c1ccc(O)cc1 |r| Show InChI InChI=1S/C32H29NO10/c34-16-9-7-14(8-10-16)30(39)33-27-20-13-21(18-4-1-3-17(18)20)29(27)43-32(42)15-11-23(36)26(24(37)12-15)28(38)25-19(31(40)41)5-2-6-22(25)35/h2,5-12,17-18,20-21,27,29,34-37H,1,3-4,13H2,(H,33,39)(H,40,41)/t17?,18?,20?,21?,27-,29-/m1/s1 | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| Article
| n/a | n/a | 150 | n/a | n/a | n/a | n/a | 7.5 | 30 |
Sphinx Laboratories
| Assay Description PKC was assayed by quantitating the incorporation of 32P from [gamma-32P]ATP into histone type IIIs. |
Bioorg Med Chem Lett 5: 2211-6 (1995)
Article DOI: 10.1016/0960-894X(95)00382-4
BindingDB Entry DOI: 10.7270/Q2QR4V9M |
More data for this Ligand-Target Pair | |